Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932321 · ClinicalTrials.gov registry record · Phase 3
Study of Safety and Efficacy of an Oral Contraceptive
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 938
- Enrollment target
NCT00932321 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 938 participants.
The verdict
NCT00932321, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 938 participants
- Enrollment target
Study Summary
This is a comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding of norethindrone acetate/ethinyl estradiol (NETA/EE) administered for 24 days and NETA/EE administered for 21 days; and to assess the safety and tolerability of the product.
Interventions
- DRUG Norethindrone Acetate/Ethinyl Estradiol 24 Days
- DRUG Norethindrone Acetate /Ethinyl Estradiol 21 Days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 938 participants |
| Start Date | 2004-01 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00932321
The ClinicalTrials.gov registry entry for NCT00932321 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 938 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Norethindrone Acetate/Ethinyl Estradiol 24 Days is the first listed.
NCT00932321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00932321 about?
NCT00932321 is a clinical study titled "Study of Safety and Efficacy of an Oral Contraceptive". This is a comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding of norethindrone acetate/ethinyl estradiol (NETA/EE) administered fo...
What is the current status of trial NCT00932321?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 938 participants. The study started on 2004-01. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00932321?
The interventions under investigation include: Norethindrone Acetate/Ethinyl Estradiol 24 Days (DRUG), Norethindrone Acetate /Ethinyl Estradiol 21 Days (DRUG).
Who is sponsoring clinical trial NCT00932321?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.